Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is an innovative biopharmaceutical company utilizing precision medicine to develop anti-cancer therapeutics, with a current focus on their lead program, Stenoparib, for advanced recurrent ovarian cancer. With a strong financial outlook and plans for expansion into both the Danish and US markets, Allarity Therapeutics is poised for success in the rapidly growing precision medicine sector. However, risks to achieving our price target include potential balance sheet and liquidity challenges, uncertainties in clinical trial results and regulatory approvals, and potential competition in the market. Overall, the company offers significant upside potential for investors with its attractive valuation and promising developments in the precision medicine space.

Bears say

Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing anti-cancer therapeutics for ovarian and small cell lung cancer. However, based on its recent Q1 results and the lack of guidance or consensus estimates, the company's minimal revenue generation and ongoing net losses are concerning. Additionally, while its DRP platform and lead drug Stenoparib show potential, there are significant risks to attaining regulatory approval and commercial success in a highly competitive PARP inhibitor market. Moreover, the company's low cash and high debt levels are a concern for investors.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.